[ad_1]
PALO ALTO, Calif., June 27, 2022 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress ™ 2022 that took place June 22-26 in London, United Kingdom.
“We are pleased that EASL recognized our HDV platform with multiple presentations this year highlighting both the lonafarnib and peginterferon lambda programs,” said David CoryPresident and CEO, Eiger. “Our Phase 3 D-LIVR study will produce the single largest cohort of patient data from a well-controlled global study of HDV. We look forward to continued collaboration with investigators and key opinion leaders to mine this deep data set, providing additional insights, with a goal of improving outcomes for the global HDV patient population. In parallel, we are preparing for topline results from the landmark D-LIVR study by end of year.”
Abstract #3442: Clinical Features Predictive of Cirrhosis in a Large Cohort of Patients with Chronic Hepatitis Delta Infection – Insights from the D-LIVR Trial; Etzion, O., Asselah, T., Lampertico, P. et al.
Conclusions: In the on-going Phase 3 D-LIVR study, the largest cohort to date of patients with…
Full story available on Benzinga.com
[ad_2]
Source link
